Biotech TV host Brad Loncar visited GRObio’s office in Cambridge and had a discussion with GRObio CEO Dan Mandell, PhD about the Company’s recent Series B financing. In the interview, Dr. Mandell explains how this funding will advance GRObio’s lead program for gout into the clinic, as well as expand the company’s pipeline and GRO platform.
